CTLA4 and neoplasm: Currently, immunotherapy for advanced LUAD mainly uses checkpoint inhibitors, such as PD-1/PD-L1 inhibitors and CTLA-4 inhibitors, to activate the patient’s own immune system to kill tumor cells.